TSLA -15.09IBM -5.13ARM -17.43CM.TO -0.79V -2.09NRIM 0CSU.TO 168.35NA.TO -1.4
Novartis AG (NVS)

NYSE:NVS

Novartis AG (NVS)

148.14
-0.98 (0.66%)
as of Jun 10, 2026, 6:33:38 pm Market Open.
44 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PAST TOP PICK

Novartis AG(NVS)

Jul 14, 2011
(A Top Pick March 25/11. Up 10.68%.) One of the few drug companies that is actually growing its earnings. Made a great acquisition in the eye care business, which is probably the fastest growing area in the medical/pharma business. Incredibly cheap.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$61.35

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novartis AG(NVS)

Mar 31, 2011
Plenty of products outstanding. Likes them in that they are trying to focus on taking one drug and using it in as many ways as possible. R&D is important. Pharmaceuticals all have a ton of cash. In the top 5 of having highest percentage of R&D to revenues. (See Top Picks.)
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$54.35

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novartis AG(NVS)

Mar 25, 2011
Has the best pipeline in the entire industry. Pharma and vaccines; Generics; and an eye care business. Just raised dividend for 14th consecutive year. Rising earnings and revenue expected, unlike rest of industry. Throw off tones of free cash flow.
Photo of Lorne SteinbergLorne Steinberg
Owned
Unlock Rating
$55.43

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novartis AG(NVS)

Dec 10, 2008
Has been quite a good performer on a relative basis as the market has turned down. Very big in the generic area. More and more generics are going to be coming forward as the medical plans improve in the US.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$45.69

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Novartis AG(NVS)

Sep 08, 2008
(Market Call Minute.) Healthcare is a group that is performing well. This one is performing better than the average pharmaceutical stock but he would prefer to go down the biotech route rather than pharmaceutical.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$52.91

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novartis AG(NVS)

Aug 28, 2008
Have defensive characteristics. Largest producer of generic drugs in the world. Good management and balance sheet.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$56.02

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novartis AG(NVS)

May 22, 2008
One of the better performing drug companies over the last several years, but suffers from what many of the drug companies suffer from; much more difficult to come up with new drugs. Well run company.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$52.80

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novartis AG(NVS)

Apr 23, 2008
Good quality company. Came down similar to most pharmaceuticals. A lot of them are having pipeline problems in getting new products to market. Relative to the US, it has a far better portfolio. OK as an entry point but he believes the sector could drop further so he would suggest you use a limit order down in a $40 range.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$49.53

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Novartis AG(NVS)

Oct 25, 2007
Has been suffering, while other drug companies have been doing very well.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$52.14

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novartis AG(NVS)

Jun 06, 2007
Prefers Rosch (ROCM-Q) over this one.
Photo of Mark GrammerMark GrammerUnlock Rating
$56.08

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novartis AG(NVS)

Mar 01, 2007
One of the more expensive healthcare stocks, which reflects the quality of its pipeline. Would prefer Johnson & Johnson (JNJ-N).
Photo of Charles LannonCharles LannonUnlock Rating
$55.10

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novartis AG(NVS)

Dec 20, 2006
The European drug stocks are cheaper than the US ones and probably have a better regulatory outlook, so owning this is not a bad idea.
Photo of Norman LevineNorman LevineUnlock Rating
$58.30

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Novartis AG(NVS)

Jul 26, 2006
The leading European pharmaceutical. Has its good points, but is in a lot of competition with the other majors. Will probably come into a little bit of a lull.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$55.99

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novartis AG(NVS)

Mar 11, 2005
We really like it. One of the few pharma companies that have a generics division embedded in it. They continue to move in the generics area because they see growth in that sector.
Photo of Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
Owned
Unlock Rating
$49.02

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novartis AG(NVS)

Aug 13, 2004
Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$45.76

Stock price when the opinion was issued

$148.12

As of Jun 10, 2026. Market Open.

biotechnologypharmaceutical
Showing 31 to 45 of 46 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

SHOP.TO -3.2$150.93
ANET -0.4$151.76
VRT -8.54$280.98
ADBE -4.5$233.38
RBLX -1.5$41.5
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TSLA -15.09$381.59
IBM -5.13$272.36
ARM -17.43$307.43
CM.TO -0.79$153.74
V -2.09$322.96

Popular Articles

Latest Sell Signals

SNOW 0.24$239.9
FLEX -7.72$139.49
MDA.TO 0.06$52.63
CPRT 0.05$31.36
TEVA -0.87$33.58

Most Recent Experts

Kim Bolton

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video